Patents by Inventor Luke O'Connor
Luke O'Connor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12204805Abstract: Systems and methods are provided for using a gesture detected at a wrist-wearable device to cause presentation of camera data at a head-wearable device. One example method includes receiving, via one or more sensors of a wrist-wearable device worn by a user, data generated based on performance of an in-air hand gesture by the user. In accordance with a determination that the data indicates that the in-air hand gesture is a camera-control gesture, the method further includes causing presentation to the user, via a display of a head-wearable device that is worn by the user and that is in communication with the wrist-wearable device, of a representation of camera data from a camera that is in communication with one or both of the wrist-wearable device and the head-wearable device.Type: GrantFiled: April 28, 2023Date of Patent: January 21, 2025Assignee: Meta Platforms Technologies, LLCInventors: Christopher Anderson, Paulo Jose Telo Coelho, Luke O'Connor, Emanuele Formento, Diego Adrian Gutnisky
-
Publication number: 20250018019Abstract: Compositions and methods for regulating immunometabolism and preventing and/or treating interferon-driven inflammation, including anti-inflammatory agents which upregulate fumarate hydratase enzymatic activity and/or expression of fumarate hydratase protein, and methods for preventing and/or treating inflammation in a patient in need thereof, wherein the methods comprise: administering an effective amount of a fumarate hydratase modulating agent to the patient.Type: ApplicationFiled: July 8, 2024Publication date: January 16, 2025Inventors: Luke O’Neill, Christian Peace, Alexander Hooftman, Dylan Ryan
-
Publication number: 20240400502Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.Type: ApplicationFiled: December 14, 2023Publication date: December 5, 2024Inventors: Luke O'NEILL, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder
-
Publication number: 20240194364Abstract: Electrolytic interior surface treatment apparatus (100) for the electrolytic treatment of an internal surface (102) of a metallic pipe (1) includes at least two oppositely polarised electrodes (3, 4). The apparatus (100) includes: an electrically insulating centralisation arrangement (106) to keep, in use, the electrodes (3, 4) centred within the pipe (1); and an electrically insulating flexible connection arrangement (104) located between the two electrodes (3, 4) to permit movement of one electrode relative to the other. The centralisation arrangement (106) includes a plurality of spaced apart centralisation devices (5, 6). Each centralisation device (5, 6) includes an electrically insulating mounting (7) for mounting the respective centralisation device (5, 6) to the apparatus (100). Each centralisation device (5, 6) includes a plurality of flexible elements (108), each of which is fixed to the mounting (7) and extends outwardly from the mounting (7).Type: ApplicationFiled: March 21, 2022Publication date: June 13, 2024Inventors: Robert BELL, John COLLINS, Luke O'BRIEN
-
Publication number: 20240170171Abstract: The invention provides electrochemical surface treatment apparatus (100) for the treatment of radioactively contaminated internal surfaces of a pipe (1). The apparatus (100) includes an electrode device (102). The device (102) includes an electrode (4), which, in use, is located in electrolyte liquid (2) within the pipe (1) adjacent a treatment surface (104) to be treated with a gap (106) defined between the electrode (4) and the treatment surface (104). The apparatus (100) includes a circulation arrangement (108). The electrode (4) defines an internal passage (110). In use, the circulation arrangement (108) causes a recirculating flow of electrolyte liquid (2) through the gap (106) in one direction and along the passage (110) in an opposite direction.Type: ApplicationFiled: March 21, 2022Publication date: May 23, 2024Inventors: Robert BELL, John COLLINS, Luke O'BRIEN
-
Publication number: 20240061514Abstract: The various implementations described herein include methods and systems for using hand gestures detected at a wearable device to navigate a user interface. An example method includes receiving, via one or more neuromuscular-signal sensors of a wrist-wearable device worn by a user, data generated during performance of an in-air wrist movement by a wrist of the user. The method also includes moving a point of focus on the user interface in accordance with the in-air wrist movement; and receiving, via the one or more neuromuscular-signal sensors, additional data generated during performance of an in-air gesture by the user. The method further includes determining that the in-air gesture is an execution gesture; and executing a command corresponding to the execution gesture.Type: ApplicationFiled: August 2, 2023Publication date: February 22, 2024Inventors: Jason Lowell Reisman, Luke O'Connor, Christopher Anderson, Adam Berenzweig, Austin Ha, Zaina Edelson, Szeyin Lee, Paulo Jose Telo Coelho, Edith Comas, Shaker Islam
-
Patent number: 11858922Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independently selected from N and C; R1 and R2 are independently selected from the group consisting of hydrogen, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W1 and W2 is present and is a nitrogen atom and when R1 or R2 are cyclic then the respective W1 or W2 may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.Type: GrantFiled: February 16, 2017Date of Patent: January 2, 2024Assignees: THE UNIVERSITY OF QUEENSLAND, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLINInventors: Luke O'Neill, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder, Angus Murray Macleod, David John Miller
-
Patent number: 11845715Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.Type: GrantFiled: August 18, 2021Date of Patent: December 19, 2023Assignees: THE UNIVERSITY OF QUEENSLAND, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLINInventors: Luke O'Neill, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder
-
Patent number: 11840543Abstract: The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP3 inhibition and the stimulation of insulin secretion.Type: GrantFiled: May 24, 2017Date of Patent: December 12, 2023Assignees: THE UNIVERSITY OF QUEENSLAND, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLINInventors: Luke O'Neill, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder, Angus Murray MacLeod, David John Miller
-
Publication number: 20230359422Abstract: Systems and methods are provided for using a gesture detected at a wrist-wearable device to cause presentation of camera data at a head-wearable device. One example method includes receiving, via one or more sensors of a wrist-wearable device worn by a user, data generated based on performance of an in-air hand gesture by the user. In accordance with a determination that the data indicates that the in-air hand gesture is a camera-control gesture, the method further includes causing presentation to the user, via a display of a head-wearable device that is worn by the user and that is in communication with the wrist-wearable device, of a representation of camera data from a camera that is in communication with one or both of the wrist-wearable device and the head-wearable device.Type: ApplicationFiled: April 28, 2023Publication date: November 9, 2023Inventors: Christopher Anderson, Paulo Jose Telo Coelho, Luke O'Connor, Emanuele Formento, Diego Adrian Gutnisky
-
Publication number: 20220112159Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.Type: ApplicationFiled: August 18, 2021Publication date: April 14, 2022Inventors: Luke O'NEILL, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder
-
Patent number: 11278593Abstract: The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation. The invention is also directed to a method for the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation and to recombinant vectors and recombinant proteins for use in such methods. The present invention also provides a method for determining the risk of developing or monitoring the progression of diseases involving drusen and anaphylatoxin-induced choroidal neo-vascularisation.Type: GrantFiled: May 2, 2019Date of Patent: March 22, 2022Assignee: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLINInventors: Matthew Campbell, Peter Humphries, Marian Humphries, Anna-Sophia Kiang, Sarah Doyle, Luke O'Neill
-
Publication number: 20210407698Abstract: An electrolytic treatment system to decontaminate the surface of a radioactively contaminated metallic workpiece has at least two electrodes in close proximity to the surface but not in direct electrical contact. The electrodes are separated from the surface by an electrolyte. Insulation is provided in the electrolyte between the electrodes to avoid or minimize a direct current path between the electrodes though the electrolyte.Type: ApplicationFiled: October 29, 2019Publication date: December 30, 2021Inventors: Robert BELL, John COLLINS, Luke O'BRIEN
-
Patent number: 11130731Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.Type: GrantFiled: August 7, 2019Date of Patent: September 28, 2021Assignees: The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin, The University Of QueenslandInventors: Luke O'Neill, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder
-
Publication number: 20200299284Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independently selected from N and C; R1 and R2 are independently selected from the group consisting of hydrogen, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W1 and W2 is present and is a nitrogen atom and when R1 or R2 are cyclic then the respective W1 or W2 may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.Type: ApplicationFiled: February 16, 2017Publication date: September 24, 2020Inventors: Luke O'NEILL, Rebecca COLL, Matthew COOPER, Avril ROBERTSON, Kate SCHRODER, Angus Murray MACLEOD, David John MILLER
-
Publication number: 20200207780Abstract: The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP3 inhibition and the stimulation of insulin secretion.Type: ApplicationFiled: May 24, 2017Publication date: July 2, 2020Inventors: Luke O'Neill, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder, Angus Murray MacLeod, David John Miller
-
Publication number: 20200172586Abstract: An isolated protein from Cimex lectularius comprising an amino acid sequence selected from any one of SEQ ID No. 1 or 5 or fragment thereof or an isolated polypeptide from Cimex lectularius comprising an amino acid sequence selected from any one or more of SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 6 and SEQ ID No. 7 or fragment thereof for use in generating antibodies to detect the presence of antigens specific for Cimex lectularius wherein the antibodies are capable of detecting Cimex lectularius antigen in all stages of Cimex lectularius development from egg, nymphs, moults to mature male and female adults at antigen concentrations of less than 20 ?g/m1.Type: ApplicationFiled: July 30, 2019Publication date: June 4, 2020Inventors: Natasha Gordon, Luke O'Shaughnessy, Bruce Mitchell
-
Patent number: 10538487Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.Type: GrantFiled: February 16, 2016Date of Patent: January 21, 2020Assignees: THE UNIVERSITY OF QUEENSLAND, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLINInventors: Luke O'Neill, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder
-
Publication number: 20190359564Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.Type: ApplicationFiled: August 7, 2019Publication date: November 28, 2019Applicants: THE UNIVERSITY OF QUEENSLAND, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLInventors: Luke O'NEILL, Rebecca COLL, Matthew COOPER, Avril ROBERTSON, Kate SCHRODER
-
Publication number: 20190314454Abstract: The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation. The invention is also directed to a method for the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation and to recombinant vectors and recombinant proteins for use in such methods. The present invention also provides a method for determining the risk of developing or monitoring the progression of diseases involving drusen and anaphylatoxin-induced choroidal neo-vascularisation.Type: ApplicationFiled: May 2, 2019Publication date: October 17, 2019Inventors: Matthew CAMPBELL, Peter HUMPHRIES, Marian HUMPHRIES, Anna-Sophia KIANG, Sarah DOYLE, Luke O'NEILL